Person · CIK 1547959

Saira Ramasastry

Former Director at Vir Biotechnology; director at Mirum Pharmaceuticals, Sensei Biotherapeutics and Day One Biopharmaceuticals

Earlier: Akouos, Sangamo Therapeutics, Innovate Biopharmaceuticals, Cassava Sciences and Repros Therapeutics

Source: Forms 3, 4, 5 and 144 on SEC EDGAR

Sold on Form 4$4.4M

Noticed on Form 144$4M

Bought on Form 4$0

Companies9

Holdings now

As reported after the latest Form 3, 4 or 5 at each company.

How these figures work

Options and RSUs are from the latest filing that lists them; earlier grants may also be held. Holdings can be out of date when a person stops filing.

Company	Security	Held	Shares or units	As of
Mirum Pharmaceuticals MIRM	Stock Option (right to buy) exercise $101.00, expires Jun 14, 2036, into Common Stock	Directly	3,772	Jun 15, 2026 · Filing · EDGAR
Mirum Pharmaceuticals MIRM	Restricted Stock Units into Common Stock	Directly	1,980	Jun 15, 2026 · Filing · EDGAR
Sensei Biotherapeutics FTH	Stock Option (right to buy) exercise $13.00, expires Jun 11, 2036, into Common Stock	Directly	25,000	Jun 12, 2026 · Filing · EDGAR
Vir Biotechnology VIR	Common Stock	Directly	22,619	May 30, 2025 · Filing · EDGAR
Vir Biotechnology VIR	Stock Option (Right to Buy) exercise $4.94, expires May 29, 2035, into Common Stock	Directly	16,000	May 30, 2025 · Filing · EDGAR
Sangamo Therapeutics	Common Stock	Directly	35,700	Feb 25, 2022 · Filing · EDGAR
Sangamo Therapeutics	Stock Option (Right to Buy) exercise $5.90, expires Feb 24, 2032, into Common Stock	Directly	25,000	Feb 25, 2022 · Filing · EDGAR
Innovate Biopharmaceuticals	Stock Option (Right to Buy) exercise $0.60, expires Apr 24, 2030, into Common stock	Directly	25,000	Apr 24, 2020 · Filing · EDGAR
Cassava Sciences	Stock Option (Right to Buy) exercise $1.88, expires Dec 13, 2029, into Common Stock	Directly	30,000	Dec 13, 2019 · Filing · EDGAR

Sold and noticed by quarter

Sold (Form 4) Noticed (Form 144) Bought (Form 4)

Quarterly totals as a table

Quarter	Sold (Form 4)	Noticed (Form 144)
Q2 2026	$810K	$976K
Q1 2026	$568K	$568K
Q4 2025	$539K	$539K
Q3 2025	—	$1.3M
Q2 2025	$378K	$378K
Q2 2024	$304K	$176K
Q2 2023	$90K	$90K
Q3 2022	$150K	Not machine-readable
Q2 2022	$40K	Not machine-readable
Q2 2021	$437K	Not machine-readable
Q4 2020	$133K	Not machine-readable
Q1 2018	$235K	Not machine-readable
Q4 2017	$73K	Not machine-readable
Q1 2015	$150K	Not machine-readable
Q3 2014	$140K	Not machine-readable
Q2 2014	$86K	Not machine-readable
Q1 2014	$233K	Not machine-readable

Form 144 notices went onto EDGAR as structured data on April 13, 2023. Earlier notices were filed on paper and cannot be read here, so those quarters show no noticed amount.

Planned sales (Form 144) and the sales that followed

Each Form 144 notice of a planned sale, grouped by broker and 10b5-1 plan, with the Form 4 sales we matched to it.

How we match

A Form 144 is a notice of a planned sale by an affiliate. SEC Tracker matches each notice to Form 4 sales by the same person at the same company within 90 days of the notice, up to the shares noticed. The match is our inference, not something either filing states.

Notice date	Noticed	Planned sale	Outcome	Links
Vir Biotechnology VIR · Fidelity Brokerage Services · No 10b5-1 plan stated · 1 notice
Jun 29, 2026	16,000 · ~$165K	Jun 29, 2026	Not sold within 90 days	Filing · EDGAR
Mirum Pharmaceuticals MIRM · Morgan Stanley Smith Barney · 10b5-1 plan adopted Sep 18, 2025 · 8 notices
Jun 1, 2026	3,977 · ~$398K	Jun 1, 2026	Sold as noticed Sold 3,977 at $100.00 on Jun 1 · $398K Form 4	Filing · EDGAR
May 15, 2026	2,000 · ~$219K	May 15, 2026	Sold as noticed Sold 2,000 at $109.47 on May 15 · $219K Form 4	Filing · EDGAR
Apr 15, 2026	2,000 · ~$194K	Apr 15, 2026	Sold as noticed Sold 2,000 at $96.90 on Apr 15 · $194K Form 4	Filing · EDGAR
Mar 16, 2026	2,000 · ~$182K	Mar 16, 2026	Sold as noticed Sold 2,000 at $90.76 on Mar 16 · $182K Form 4	Filing · EDGAR
Feb 13, 2026	2,000 · ~$204K	Feb 13, 2026	Sold as noticed Sold 2,000 at $102.09 on Feb 13 · $204K Form 4	Filing · EDGAR
Jan 15, 2026	2,000 · ~$182K	Jan 15, 2026	Sold as noticed Sold 2,000 at $90.99 on Jan 15 · $182K Form 4	Filing · EDGAR
Dec 22, 2025	5,000 · ~$400K	Dec 22, 2025	Sold as noticed Sold 5,000 at $80.00 on Dec 22 · $400K Form 4	Filing · EDGAR
Dec 18, 2025	2,000 · ~$139K	Dec 18, 2025	Sold as noticed Sold 2,000 in 2 sales, Dec 18 to Dec 18 · $139K Form 4	Filing · EDGAR
Mirum Pharmaceuticals MIRM · Morgan Stanley Smith Barney · No 10b5-1 plan stated · 3 notices
Sep 8, 2025	17,000 · ~$1.3M	Sep 8, 2025	Sold as noticed Sold 17,000 on Sep 8 Form 4	Filing · EDGAR
Jun 3, 2025	2,500 · ~$114K	Jun 3, 2025	Sold as noticed Sold 2,500 at $45.74 on Jun 3 · $114K Form 4	Filing · EDGAR
Jun 2, 2025	5,703 · ~$263K	Jun 2, 2025	Sold as noticed Sold 5,703 at $46.20 on Jun 2 · $263K Form 4	Filing · EDGAR
Day One Biopharmaceuticals DAWN · Morgan Stanley Smith Barney · No 10b5-1 plan stated · 1 notice
Jun 21, 2024	10,000 · ~$132K	Jun 21, 2024	Sold as noticed Sold 10,000 at $13.19 on Jun 21 · $132K Form 4	Filing · EDGAR
Vir Biotechnology VIR · Morgan Stanley Smith Barney · No 10b5-1 plan stated · 1 notice
Jun 11, 2024	4,000 · ~$44K	Jun 11, 2024	Sold as noticed Sold 4,000 at $10.95 on Jun 11 · $44K Form 4	Filing · EDGAR
Vir Biotechnology VIR · E*Trade Financial · 10b5-1 plan adopted Mar 2, 2023 · 1 notice
Jun 1, 2023	3,500 · ~$90K	Jun 1, 2023	Sold as noticed Sold 3,500 at $25.67 on Jun 1 · $90K Form 4	Filing · EDGAR
Sales without a matching Form 144 · 11 sales No matching Form 144 found. Not every sale needs one: small sales and sales by people who are not affiliates are exempt.
—	—	—	Sold without notice Mirum Pharmaceuticals (MIRM): Sold 5,000 at $25.68 on Jun 5, 2024 · $128K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Vir Biotechnology (VIR): Sold 5,000 at $30.00 on Jul 11, 2022 · $150K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Vir Biotechnology (VIR): Sold 1,687 at $23.82 on May 24, 2022 · $40K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Vir Biotechnology (VIR): Sold 10,000 at $43.73 on May 19, 2021 · $437K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Sangamo Therapeutics: Sold 10,000 at $13.27 on Dec 17, 2020 · $133K	Filing · EDGAR
—	—	—	Notice not machine-readable Sangamo Therapeutics: Sold 9,450 at $24.88 on Feb 26, 2018 · $235K	Filing · EDGAR
—	—	—	Notice not machine-readable Sangamo Therapeutics: Sold 5,000 at $14.67 on Nov 17, 2017 · $73K	Filing · EDGAR
—	—	—	Notice not machine-readable Sangamo Therapeutics: Sold 10,000 at $15.00 on Feb 12, 2015 · $150K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Sangamo Therapeutics: Sold 10,000 at $14.00 on Aug 8, 2014 · $140K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Sangamo Therapeutics: Sold 5,550 at $15.53 on Jun 23, 2014 · $86K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Sangamo Therapeutics: Sold 10,000 at $23.26 on Mar 17, 2014 · $233K (10b5-1 plan)	Filing · EDGAR

Every transaction, by company

Each Form 3, 4 and 5 transaction in plain words, newest first.

How these figures work

Values are shares times the price each filing states; grants, exercises and gifts usually state no price. Held after is what the filing reports was held once the transaction was done, directly or through the named holder.

Vir Biotechnology VIR Former Director · filings 2019 to 2026 · sold $761K · $299K noticed on Form 144

Date	Transaction	Shares	Price	Value	Held after	Source
May 30, 2025	Grant or award from the company	+8,000			22,619 direct	Filing · EDGAR
May 30, 2025	Grant or award from the company Stock Option (Right to Buy)	+16,000			16,000 direct	Filing · EDGAR
Jun 11, 2024	Open-market or private sale	−4,000	$10.95	$44K	14,619 direct	Filing · EDGAR
May 30, 2024	Grant or award from the company	+8,000			18,619 direct	Filing · EDGAR
May 30, 2024	Grant or award from the company Stock Option (Right to Buy)	+16,000			16,000 direct	Filing · EDGAR
Jun 1, 2023	Sale under a 10b5-1 plan	−3,500	$25.67	$90K	10,619 direct	Filing · EDGAR
May 22, 2023	Grant or award from the company	+6,027			14,119 direct	Filing · EDGAR
May 22, 2023	Grant or award from the company Stock Option (Right to Buy)	+12,054			12,054 direct	Filing · EDGAR
Jul 11, 2022	Grant or award from the company	+5,000	$12.76	$64K	13,092 direct	Filing · EDGAR
Jul 11, 2022	Sale under a 10b5-1 plan	−5,000	$30.00	$150K	8,092 direct	Filing · EDGAR
Jul 11, 2022	Option or RSU exercised or converted Stock Option (Right to Buy)	−5,000			42,777 direct	Filing · EDGAR
May 24, 2022	Sale under a 10b5-1 plan	−1,687	$23.82	$40K	8,092 direct	Filing · EDGAR
May 23, 2022	Grant or award from the company	+6,405			9,779 direct	Filing · EDGAR
May 23, 2022	Grant or award from the company Stock Option (Right to Buy)	+12,810			12,810 direct	Filing · EDGAR
May 21, 2021	Grant or award from the company	+3,374			3,374 direct	Filing · EDGAR
May 21, 2021	Grant or award from the company Stock Option (Right to Buy)	+6,748			6,748 direct	Filing · EDGAR
May 19, 2021	Option or RSU exercised or converted	+10,000	$12.76	$128K	10,000 direct	Filing · EDGAR
May 19, 2021	Sale under a 10b5-1 plan	−10,000	$43.73	$437K	0 direct	Filing · EDGAR
May 19, 2021	Option or RSU exercised or converted Stock Option (Right to Buy)	−10,000			47,777 direct	Filing · EDGAR
May 21, 2020	Grant or award from the company Stock Option (Right to Buy)	+24,497			24,497 direct	Filing · EDGAR
Dec 10, 2019	Grant or award from the company Stock Option (Right to Buy)	+57,777			57,777 direct	Filing · EDGAR

Mirum Pharmaceuticals MIRM Director · filings 2022 to 2026 · sold $2.4M · $3.6M noticed on Form 144

Date	Transaction	Shares	Price	Value	Held after	Source
Jun 15, 2026	Grant or award from the company Stock Option (right to buy)	+3,772			3,772 direct	Filing · EDGAR
Jun 15, 2026	Grant or award from the company Restricted Stock Units	+1,980			1,980 direct	Filing · EDGAR
Jun 1, 2026	Sale under a 10b5-1 plan	−3,977	$100.00	$398K	0 direct	Filing · EDGAR
May 29, 2026	Option or RSU exercised or converted	+3,977			3,977 direct	Filing · EDGAR
May 29, 2026	Option or RSU exercised or converted Restricted Stock Units	−3,977			0 direct	Filing · EDGAR
May 15, 2026	Option or RSU exercised or converted	+2,000	$23.51	$47K	2,000 direct	Filing · EDGAR
May 15, 2026	Sale under a 10b5-1 plan	−2,000	$109.47	$219K	0 direct	Filing · EDGAR
May 15, 2026	Option or RSU exercised or converted Stock Option (right to buy)	−2,000			0 direct	Filing · EDGAR
Apr 15, 2026	Option or RSU exercised or converted	+2,000	$23.51	$47K	2,000 direct	Filing · EDGAR
Apr 15, 2026	Sale under a 10b5-1 plan	−2,000	$96.90	$194K	0 direct	Filing · EDGAR
Apr 15, 2026	Option or RSU exercised or converted Stock Option (right to buy)	−2,000			2,000 direct	Filing · EDGAR
Mar 16, 2026	Option or RSU exercised or converted	+2,000	$23.51	$47K	2,000 direct	Filing · EDGAR
Mar 16, 2026	Sale under a 10b5-1 plan	−2,000	$90.76	$182K	0 direct	Filing · EDGAR
Mar 16, 2026	Option or RSU exercised or converted Stock Option (right to buy)	−2,000			4,000 direct	Filing · EDGAR
Feb 13, 2026	Option or RSU exercised or converted	+2,000	$23.51	$47K	2,000 direct	Filing · EDGAR
Feb 13, 2026	Sale under a 10b5-1 plan	−2,000	$102.09	$204K	0 direct	Filing · EDGAR
Feb 13, 2026	Option or RSU exercised or converted Stock Option (right to buy)	−2,000			6,000 direct	Filing · EDGAR
Jan 15, 2026	Option or RSU exercised or converted	+2,000	$23.51	$47K	2,000 direct	Filing · EDGAR
Jan 15, 2026	Sale under a 10b5-1 plan	−2,000	$90.99	$182K	0 direct	Filing · EDGAR
Jan 15, 2026	Option or RSU exercised or converted Stock Option (right to buy)	−2,000			8,000 direct	Filing · EDGAR
Dec 22, 2025	Option or RSU exercised or converted	+5,000	$23.51	$118K	5,000 direct	Filing · EDGAR
Dec 22, 2025	Sale under a 10b5-1 plan	−5,000	$80.00	$400K	0 direct	Filing · EDGAR
Dec 22, 2025	Option or RSU exercised or converted Stock Option (right to buy)	−5,000			10,000 direct	Filing · EDGAR
Dec 18, 2025	Option or RSU exercised or converted	+2,000	$23.51	$47K	2,000 direct	Filing · EDGAR
Dec 18, 2025	Sale under a 10b5-1 plan	−1,000	$69.46	$69K	1,000 direct	Filing · EDGAR
Dec 18, 2025	Sale under a 10b5-1 plan	−1,000	$70.00	$70K	0 direct	Filing · EDGAR
Dec 18, 2025	Option or RSU exercised or converted Stock Option (right to buy)	−2,000			15,000 direct	Filing · EDGAR
Sep 8, 2025	Option or RSU exercised or converted	+17,000	$23.51	$400K	17,000 direct	Filing · EDGAR
Sep 8, 2025	Open-market or private sale	−17,000			0 direct	Filing · EDGAR
Sep 8, 2025	Option or RSU exercised or converted Stock Option (right to buy)	−17,000			17,000 direct	Filing · EDGAR
Jun 3, 2025	Option or RSU exercised or converted	+2,500	$14.12	$35K	2,500 direct	Filing · EDGAR
Jun 3, 2025	Open-market or private sale	−2,500	$45.74	$114K	0 direct	Filing · EDGAR
Jun 3, 2025	Option or RSU exercised or converted Stock Option (right to buy)	−2,500			0 direct	Filing · EDGAR
Jun 2, 2025	Open-market or private sale	−5,703	$46.20	$263K	0 direct	Filing · EDGAR
May 29, 2025	Option or RSU exercised or converted	+5,703			5,703 direct	Filing · EDGAR
May 29, 2025	Option or RSU exercised or converted Restricted Stock Units	−5,703			0 direct	Filing · EDGAR
May 29, 2025	Grant or award from the company Stock Option (right to buy)	+6,268			6,268 direct	Filing · EDGAR
May 29, 2025	Grant or award from the company Restricted Stock Units	+3,977			3,977 direct	Filing · EDGAR
Jun 5, 2024	Option or RSU exercised or converted	+5,000	$14.12	$71K	5,000 direct	Filing · EDGAR
Jun 5, 2024	Sale under a 10b5-1 plan	−5,000	$25.68	$128K	0 direct	Filing · EDGAR
Jun 5, 2024	Option or RSU exercised or converted Stock Option (right to buy)	−5,000			2,500 direct	Filing · EDGAR
Jun 5, 2024	Grant or award from the company Stock Option (right to buy)	+8,779			8,779 direct	Filing · EDGAR
Jun 5, 2024	Grant or award from the company Restricted Stock Units	+5,703			5,703 direct	Filing · EDGAR
Jun 12, 2023	Grant or award from the company Stock Option (right to buy)	+17,000			17,000 direct	Filing · EDGAR
Jun 2, 2022	Grant or award from the company Stock Option (right to buy)	+34,000			34,000 direct	Filing · EDGAR

Sensei Biotherapeutics FTH Director · filings 2026 to 2026

Date	Transaction	Shares	Price	Value	Held after	Source
Jun 12, 2026	Grant or award from the company Stock Option (right to buy)	+25,000			25,000 direct	Filing · EDGAR

Day One Biopharmaceuticals DAWN Director · filings 2021 to 2026 · sold $132K · $132K noticed on Form 144

Date	Transaction	Shares	Price	Value	Held after	Source
Apr 23, 2026	Returned to the company	−40,485	$0.00	$4	0 direct	Filing · EDGAR
Apr 23, 2026	Returned to the company Stock Option (right to buy Common Stock)	−40,000			0 direct	Filing · EDGAR
Apr 23, 2026	Returned to the company Stock Option (right to buy Common Stock)	−47,581			0 direct	Filing · EDGAR
Apr 23, 2026	Returned to the company Stock Option (right to buy Common Stock)	−28,700			0 direct	Filing · EDGAR
Apr 23, 2026	Returned to the company Stock Option (right to buy Common Stock)	−37,500			0 direct	Filing · EDGAR
Apr 23, 2026	Returned to the company Stock Option (right to buy Common Stock)	−32,335			0 direct	Filing · EDGAR
Apr 23, 2026	Returned to the company Stock Option (right to buy Common Stock)	−22,500			0 direct	Filing · EDGAR
Apr 23, 2026	Returned to the company Restricted Stock Unit (RSU)	−15,000			0 direct	Filing · EDGAR
Nov 6, 2025	Returned to the company Stock Option (right to buy Common Stock)	−40,000			0 direct	Filing · EDGAR
Nov 6, 2025	Grant or award from the company Stock Option (right to buy Common Stock)	+40,000			40,000 direct	Filing · EDGAR
Nov 6, 2025	Returned to the company Stock Option (right to buy Common Stock)	−47,581			0 direct	Filing · EDGAR
Nov 6, 2025	Grant or award from the company Stock Option (right to buy Common Stock)	+47,581			47,581 direct	Filing · EDGAR
Nov 6, 2025	Returned to the company Stock Option (right to buy Common Stock)	−28,700			0 direct	Filing · EDGAR
Nov 6, 2025	Grant or award from the company Stock Option (right to buy Common Stock)	+28,700			28,700 direct	Filing · EDGAR
Nov 6, 2025	Returned to the company Stock Option (right to buy Common Stock)	−37,500			0 direct	Filing · EDGAR
Nov 6, 2025	Grant or award from the company Stock Option (right to buy Common Stock)	+37,500			37,500 direct	Filing · EDGAR
Nov 6, 2025	Returned to the company Stock Option (right to buy Common Stock)	−32,335			0 direct	Filing · EDGAR
Nov 6, 2025	Grant or award from the company Stock Option (right to buy Common Stock)	+32,335			32,335 direct	Filing · EDGAR
Jun 2, 2025	Grant or award from the company Stock Option (right to buy Common Stock)	+22,500			22,500 direct	Filing · EDGAR
Jun 2, 2025	Grant or award from the company Deferred Restricted Stock Unit (RSU)	+15,000			15,000 direct	Filing · EDGAR
Jun 21, 2024	Open-market or private sale	−10,000	$13.19	$132K	40,485 direct	Filing · EDGAR
May 23, 2024	Grant or award from the company Stock Option (right to buy Common Stock)	+32,335			32,335 direct	Filing · EDGAR
Jun 22, 2023	Grant or award from the company Director Stock Option (Right to buy Common Stock)	+37,500			37,500 direct	Filing · EDGAR
Jun 21, 2022	Grant or award from the company Director Stock Option (Right to buy Common Stock)	+28,700			28,700 direct	Filing · EDGAR

Akouos Director · filings 2020 to 2022

Date	Transaction	Shares	Held after	Source
Dec 1, 2022	Returned to the company Stock Option (right to buy)	−16,000	0 direct	Filing · EDGAR
Jun 23, 2022	Grant or award from the company Stock Option (right to buy)	+16,000	16,000 direct	Filing · EDGAR
Jun 24, 2021	Grant or award from the company Stock Option (right to buy)	+16,000	16,000 direct	Filing · EDGAR
Jun 26, 2020	Grant or award from the company Stock Option (right to buy)	+22,625	22,625 direct	Filing · EDGAR

Sangamo Therapeutics Director · filings 2012 to 2022 · sold $1M

Date	Transaction	Shares	Price	Value	Held after	Source
Feb 25, 2022	Grant or award from the company	+12,500			35,700 direct	Filing · EDGAR
Feb 25, 2022	Grant or award from the company Stock Option (Right to Buy)	+25,000			25,000 direct	Filing · EDGAR
Feb 25, 2021	Grant or award from the company	+8,200			23,200 direct	Filing · EDGAR
Feb 25, 2021	Grant or award from the company Stock Option (Right to Buy)	+16,400			16,400 direct	Filing · EDGAR
Dec 17, 2020	Option or RSU exercised or converted	+10,000	$5.99	$60K	25,000 direct	Filing · EDGAR
Dec 17, 2020	Open-market or private sale	−10,000	$13.27	$133K	15,000 direct	Filing · EDGAR
Dec 17, 2020	Option or RSU exercised or converted Stock Option (Right-to-Buy)	−10,000			0 direct	Filing · EDGAR
May 18, 2020	Grant or award from the company	+10,000			15,000 direct	Filing · EDGAR
May 18, 2020	Grant or award from the company Stock Option (Right to Buy)	+20,000			20,000 direct	Filing · EDGAR
Jun 10, 2019	Grant or award from the company	+2,500			5,000 direct	Filing · EDGAR
Jun 10, 2019	Grant or award from the company Stock Option (Right to Buy)	+15,000			15,000 direct	Filing · EDGAR
Jun 11, 2018	Grant or award from the company	+2,500			2,500 direct	Filing · EDGAR
Jun 11, 2018	Grant or award from the company Stock Option (Right to Buy)	+15,000			15,000 direct	Filing · EDGAR
Feb 26, 2018	Option or RSU exercised or converted	+9,450	$5.03	$48K	9,450 direct	Filing · EDGAR
Feb 26, 2018	Open-market or private sale	−9,450	$24.88	$235K	0 direct	Filing · EDGAR
Feb 26, 2018	Option or RSU exercised or converted Stock Option (Right to Buy)	−9,450			0 direct	Filing · EDGAR
Nov 17, 2017	Option or RSU exercised or converted	+5,000	$5.03	$25K	5,000 direct	Filing · EDGAR
Nov 17, 2017	Open-market or private sale	−5,000	$14.67	$73K	0 direct	Filing · EDGAR
Nov 17, 2017	Option or RSU exercised or converted Stock Option (Right to Buy)	−5,000			9,450 direct	Filing · EDGAR
Jun 5, 2017	Grant or award from the company Stock Option (Right to Buy)	−10,000			10,000 direct	Filing · EDGAR
Jun 14, 2016	Grant or award from the company Employee Stock Option (Right to Buy)	−10,000			10,000 direct	Filing · EDGAR
Jun 22, 2015	Option or RSU exercised or converted Employee Stock Option (Right to Buy)	−10,000			10,000 direct	Filing · EDGAR
Feb 12, 2015	Option or RSU exercised or converted	+10,000	$5.03	$50K	10,000 direct	Filing · EDGAR
Feb 12, 2015	Sale under a 10b5-1 plan	−10,000	$15.00	$150K	0 direct	Filing · EDGAR
Feb 12, 2015	Option or RSU exercised or converted Employee Stock Option (Right to Buy)	−10,000			14,450 direct	Filing · EDGAR
Aug 8, 2014	Option or RSU exercised or converted	+10,000	$5.03	$50K	10,000 direct	Filing · EDGAR
Aug 8, 2014	Sale under a 10b5-1 plan	−10,000	$14.00	$140K	0 direct	Filing · EDGAR
Aug 8, 2014	Option or RSU exercised or converted Employee Stock Option (Right to Buy)	−10,000			24,450 direct	Filing · EDGAR
Jun 23, 2014	Option or RSU exercised or converted	+5,550	$5.03	$28K	5,550 direct	Filing · EDGAR
Jun 23, 2014	Sale under a 10b5-1 plan	−5,550	$15.53	$86K	0 direct	Filing · EDGAR
Jun 23, 2014	Option or RSU exercised or converted Employee Stock Option (Right to Buy)	−5,550			34,450 direct	Filing · EDGAR
Apr 21, 2014	Grant or award from the company Employee Stock Option (Right to Buy)	+10,000			10,000 direct	Filing · EDGAR
Mar 17, 2014	Option or RSU exercised or converted	+10,000	$5.03	$50K	10,000 direct	Filing · EDGAR
Mar 17, 2014	Sale under a 10b5-1 plan	−10,000	$23.26	$233K	0 direct	Filing · EDGAR
Mar 17, 2014	Option or RSU exercised or converted Employee Stock Option (Right to Buy)	−10,000			40,000 direct	Filing · EDGAR
Jun 12, 2013	Grant or award from the company Employee Stock Option (Right to Buy)	+10,000			10,000 direct	Filing · EDGAR
Jun 21, 2012	Grant or award from the company Stock Option (Right to Buy)	+50,000			50,000 direct	Filing · EDGAR

Innovate Biopharmaceuticals Director · filings 2018 to 2020

Date	Transaction	Shares	Held after	Source
Apr 24, 2020	Grant or award from the company Stock Option (Right to Buy)	+25,000	25,000 direct	Filing · EDGAR
May 31, 2019	Grant or award from the company Stock Option (Right to Buy)	+25,000	25,000 direct	Filing · EDGAR
Dec 4, 2018	Grant or award from the company Stock Option (Right to Buy)	+50,000	50,000 direct	Filing · EDGAR
Dec 4, 2018	Grant or award from the company Stock Option (Right to Buy)	+25,000	25,000 direct	Filing · EDGAR

Cassava Sciences Director · filings 2013 to 2019

Date	Transaction	Shares	Price	Value	Held after	Source
Dec 13, 2019	Grant or award from the company Stock Option (Right to Buy)	+30,000			30,000 direct	Filing · EDGAR
Sep 14, 2018	Grant or award from the company Stock Options(1)	+15,000	$0.95	$14K	94,991 direct	Filing · EDGAR
Dec 6, 2017	Grant or award from the company Non-Qualifying Stock Options (1)	+22,500	$4.09	$92K	79,991 direct	Filing · EDGAR
Jun 16, 2017	Grant or award from the company Non-Qualifying Stock Options (1)	+2,500	$4.10	$10K	57,500 direct	Filing · EDGAR
May 4, 2017	Grant or award from the company Non-Qualifying Stock Options (1)	+50,000	$0.78	$39K	385,000 direct	Filing · EDGAR
Jun 24, 2016	Grant or award from the company Non-Qualifying Stock Options (1)	+15,000	$2.03	$30K	335,000 direct	Filing · EDGAR
May 12, 2016	Grant or award from the company Non-Qualifying Stock Options (1)	+50,000	$2.38	$119K	320,000 direct	Filing · EDGAR
Jun 19, 2015	Grant or award from the company Non-Qualifying Stock Options (1)	+15,000	$1.77	$27K	270,000 direct	Filing · EDGAR
May 14, 2015	Grant or award from the company Non-Qualifying Stock Options (1)	+50,000	$2.23	$112K	255,000 direct	Filing · EDGAR
Dec 12, 2014	Grant or award from the company Non-Qualifying Stock Options (1)	+50,000	$1.86	$93K	205,000 direct	Filing · EDGAR
Jun 13, 2014	Grant or award from the company Non-Qualifying Stock Options (1)	+15,000	$5.20	$78K	155,000 direct	Filing · EDGAR
May 16, 2014	Grant or award from the company Non-Qualifying Stock Options (1)	+50,000	$4.59	$230K	140,000 direct	Filing · EDGAR
Jun 14, 2013	Grant or award from the company Non-Qualifying Stock Options (1)	+25,000	$2.38	$60K	75,000 direct	Filing · EDGAR
Jun 14, 2013	Grant or award from the company Non-Qualifying Stock Options (2)	+15,000	$2.38	$36K	90,000 direct	Filing · EDGAR
May 16, 2013	Grant or award from the company Non-Qualifying Stock Options (1)	+25,000	$2.80	$70K	50,000 direct	Filing · EDGAR

Repros Therapeutics Director · filings 2013 to 2018

Date	Transaction	Shares	Price	Value	Held after	Source
Jan 31, 2018	Returned to the company	−27,779	$0.67	$19K	0 direct	Filing · EDGAR
Jan 31, 2018	Returned to the company Stock Option	−5,000			0 direct	Filing · EDGAR
Jan 29, 2018	Tendered in a change of control	−12,221	$0.67	$8K	27,779 direct	Filing · EDGAR
Sep 15, 2017	Grant or award from the company Stock Option	+5,000			5,000 direct	Filing · EDGAR
Feb 13, 2017	Grant or award from the company	+40,000			40,000 direct	Filing · EDGAR
Jun 30, 2016	Grant or award from the company Stock Option	+5,000			5,000 direct	Filing · EDGAR
May 28, 2015	Grant or award from the company Stock Option	+5,000			5,000 direct	Filing · EDGAR
Feb 5, 2015	Grant or award from the company Stock Option (right to buy Common Stock)	+30,000			30,000 direct	Filing · EDGAR
Jun 16, 2014	Grant or award from the company Stock Option	+5,000			5,000 direct	Filing · EDGAR
Jun 18, 2013	Grant or award from the company Stock Option	+5,000			45,000 direct	Filing · EDGAR

All 107 Forms 3, 4, 5 and 144

Filed	Form	Company	Links
Jun 29, 2026	Form 144	Vir Biotechnology VIR	Filing · EDGAR
Jun 17, 2026	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Jun 16, 2026	Form 4	Sensei Biotherapeutics FTH	Filing · EDGAR
Jun 16, 2026	Form 3	Sensei Biotherapeutics FTH	Filing · EDGAR
Jun 2, 2026	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Jun 1, 2026	Form 144	Mirum Pharmaceuticals MIRM	Filing · EDGAR
May 18, 2026	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
May 15, 2026	Form 144	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Apr 23, 2026	Form 4	Day One Biopharmaceuticals DAWN	Filing · EDGAR
Apr 16, 2026	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Apr 15, 2026	Form 144	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Mar 17, 2026	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Mar 16, 2026	Form 144	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Feb 17, 2026	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Feb 13, 2026	Form 144	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Jan 16, 2026	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Jan 15, 2026	Form 144	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Dec 23, 2025	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Dec 22, 2025	Form 144	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Dec 19, 2025	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Dec 18, 2025	Form 144	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Nov 7, 2025	Form 4	Day One Biopharmaceuticals DAWN	Filing · EDGAR
Sep 10, 2025	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Sep 8, 2025	Form 144	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Jun 4, 2025	Form 4	Day One Biopharmaceuticals DAWN	Filing · EDGAR
Jun 4, 2025	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Jun 3, 2025	Form 144	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Jun 2, 2025	Form 144	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Jun 2, 2025	Form 4	Vir Biotechnology VIR	Filing · EDGAR
Jun 2, 2025	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Jun 21, 2024	Form 144	Day One Biopharmaceuticals DAWN	Filing · EDGAR
Jun 21, 2024	Form 4	Day One Biopharmaceuticals DAWN	Filing · EDGAR
Jun 12, 2024	Form 4	Vir Biotechnology VIR	Filing · EDGAR
Jun 11, 2024	Form 144	Vir Biotechnology VIR	Filing · EDGAR
Jun 7, 2024	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Jun 3, 2024	Form 4	Vir Biotechnology VIR	Filing · EDGAR
May 28, 2024	Form 4	Day One Biopharmaceuticals DAWN	Filing · EDGAR
Jun 26, 2023	Form 4	Day One Biopharmaceuticals DAWN	Filing · EDGAR
Jun 14, 2023	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Jun 2, 2023	Form 4	Vir Biotechnology VIR	Filing · EDGAR
Jun 1, 2023	Form 144	Vir Biotechnology VIR	Filing · EDGAR
May 24, 2023	Form 4	Vir Biotechnology VIR	Filing · EDGAR
Dec 2, 2022	Form 4	Akouos	Filing · EDGAR
Jul 13, 2022	Form 4	Vir Biotechnology VIR	Filing · EDGAR
Jun 27, 2022	Form 4	Akouos	Filing · EDGAR
Jun 23, 2022	Form 4	Day One Biopharmaceuticals DAWN	Filing · EDGAR
Jun 7, 2022	Form 3	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Jun 6, 2022	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
May 25, 2022	Form 4	Vir Biotechnology VIR	Filing · EDGAR
Mar 1, 2022	Form 4	Sangamo Therapeutics	Filing · EDGAR
Jun 25, 2021	Form 4	Akouos	Filing · EDGAR
May 26, 2021	Form 3	Day One Biopharmaceuticals DAWN	Filing · EDGAR
May 25, 2021	Form 4	Vir Biotechnology VIR	Filing · EDGAR
May 20, 2021	Form 4	Vir Biotechnology VIR	Filing · EDGAR
Mar 1, 2021	Form 4	Sangamo Therapeutics	Filing · EDGAR
Dec 18, 2020	Form 4	Sangamo Therapeutics	Filing · EDGAR
Oct 13, 2020	Form 4/A	Vir Biotechnology VIR	Filing · EDGAR
Jun 30, 2020	Form 4	Akouos	Filing · EDGAR
Jun 25, 2020	Form 3	Akouos	Filing · EDGAR
Jun 3, 2020	Form 4/A	Sangamo Therapeutics	Filing · EDGAR
May 26, 2020	Form 4	Vir Biotechnology VIR	Filing · EDGAR
May 20, 2020	Form 4	Sangamo Therapeutics	Filing · EDGAR
May 4, 2020	Form 4	Innovate Biopharmaceuticals	Filing · EDGAR
Dec 16, 2019	Form 4	Cassava Sciences	Filing · EDGAR
Dec 12, 2019	Form 4	Vir Biotechnology VIR	Filing · EDGAR
Oct 10, 2019	Form 3	Vir Biotechnology VIR	Filing · EDGAR
Jun 12, 2019	Form 4	Sangamo Therapeutics	Filing · EDGAR
Jun 4, 2019	Form 4	Innovate Biopharmaceuticals	Filing · EDGAR
Dec 7, 2018	Form 4	Innovate Biopharmaceuticals	Filing · EDGAR
Sep 18, 2018	Form 4	Cassava Sciences	Filing · EDGAR
Jun 20, 2018	Form 3	Innovate Biopharmaceuticals	Filing · EDGAR
Jun 12, 2018	Form 4	Sangamo Therapeutics	Filing · EDGAR
Feb 27, 2018	Form 4	Sangamo Therapeutics	Filing · EDGAR
Jan 31, 2018	Form 4	Repros Therapeutics	Filing · EDGAR
Dec 8, 2017	Form 4	Cassava Sciences	Filing · EDGAR
Nov 21, 2017	Form 4	Sangamo Therapeutics	Filing · EDGAR
Sep 18, 2017	Form 4	Repros Therapeutics	Filing · EDGAR
Jun 19, 2017	Form 4	Cassava Sciences	Filing · EDGAR
Jun 7, 2017	Form 4	Sangamo Therapeutics	Filing · EDGAR
May 5, 2017	Form 4	Cassava Sciences	Filing · EDGAR
Feb 15, 2017	Form 4	Repros Therapeutics	Filing · EDGAR
Jul 5, 2016	Form 4	Repros Therapeutics	Filing · EDGAR
Jun 28, 2016	Form 4	Cassava Sciences	Filing · EDGAR
Jun 15, 2016	Form 4	Sangamo Therapeutics	Filing · EDGAR
May 18, 2016	Form 4	Cassava Sciences	Filing · EDGAR
Jun 24, 2015	Form 4	Cassava Sciences	Filing · EDGAR
Jun 24, 2015	Form 4	Sangamo Therapeutics	Filing · EDGAR
Jun 1, 2015	Form 4	Repros Therapeutics	Filing · EDGAR
May 18, 2015	Form 4	Cassava Sciences	Filing · EDGAR
Feb 13, 2015	Form 4	Sangamo Therapeutics	Filing · EDGAR
Feb 9, 2015	Form 4	Repros Therapeutics	Filing · EDGAR
Dec 16, 2014	Form 4	Cassava Sciences	Filing · EDGAR
Aug 12, 2014	Form 4	Sangamo Therapeutics	Filing · EDGAR
Jun 25, 2014	Form 4	Sangamo Therapeutics	Filing · EDGAR
Jun 17, 2014	Form 4	Cassava Sciences	Filing · EDGAR
Jun 17, 2014	Form 4	Repros Therapeutics	Filing · EDGAR
May 19, 2014	Form 4	Cassava Sciences	Filing · EDGAR
Apr 23, 2014	Form 4	Sangamo Therapeutics	Filing · EDGAR
Mar 17, 2014	Form 4	Sangamo Therapeutics	Filing · EDGAR
Jun 21, 2013	Form 4	Repros Therapeutics	Filing · EDGAR
Jun 19, 2013	Form 4	Cassava Sciences	Filing · EDGAR
Jun 14, 2013	Form 4	Sangamo Therapeutics	Filing · EDGAR
May 28, 2013	Form 4	Cassava Sciences	Filing · EDGAR
Apr 1, 2013	Form 3	Repros Therapeutics	Filing · EDGAR
Feb 12, 2013	Form 3	Cassava Sciences	Filing · EDGAR
Jun 25, 2012	Form 4	Sangamo Therapeutics	Filing · EDGAR
Jun 25, 2012	Form 3	Sangamo Therapeutics	Filing · EDGAR

Every figure is as filed with the SEC on Forms 3, 4, 5 and 144. Holdings are the amounts reported after each person's latest filing at each company and can be out of date. Matching a Form 144 notice to Form 4 sales is SEC Tracker's inference from owner, company, dates and share counts, not something the filings state. Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched Nov 6, 2026, 2:35 AM ET. The filing on SEC.gov is the record.